Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
This article was originally published in The Pink Sheet Daily
Executive SummaryNovartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.
You may also be interested in...
A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.